Spots Global Cancer Trial Database for liver transplant
Every month we try and update this database with for liver transplant cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| HepatoPredict Prognostic Tool for the Decision of Liver Transplant in Hepatocellular Carcinoma | NCT04499833 | Hepatocellular ... Recurrence Tumo... | liver transplan... | 18 Years - 70 Years | Centro Hospitalar de Lisboa Central | |
| Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant | NCT03960008 | Hepatocellular ... HCC | Stereotactic Bo... Trans-Arterial ... Doxorubin | 18 Years - | Lahey Clinic | |
| Optimizing Y90 Therapy for Radiation Lobectomy | NCT04390724 | HCC Resection Transplant Metastatic Canc... Adult Primary L... | Y90 radioemboli... | 18 Years - | Northwestern University | |
| Long-term Outcomes of Ablation, Liver Resection, and Liver Transplant as First-line Treatment for Solitary HCC of 3 cm or Less | NCT05193253 | Hepatocellular ... | Radiofrequency ... Liver resection Liver transplan... | 18 Years - | University Health Network, Toronto | |
| PET TDM FDG-Choline as a Decision-making Tool for Routine Care on the Liver Transplant List for HCC | NCT04792801 | Hepatocellular ... Liver Transplan... | PET TDM FDG-Cho... | 18 Years - | University Hospital, Lille | |
| Indocyanine Green Clearance Test in Liver Transplantation (LivInG) | NCT05228587 | Hepatic and Hep... | Indocyanine gre... | 18 Years - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant | NCT03960008 | Hepatocellular ... HCC | Stereotactic Bo... Trans-Arterial ... Doxorubin | 18 Years - | Lahey Clinic | |
| Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation | NCT06041490 | Liver Transplan... Hepatocarcinoma Recurrent Osteo... High-Risk Cance... | multi-kinase in... | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| Microbiota Study in Liver Transplanted Patients | NCT03507140 | Cirrhosis Hepatocellular ... Liver Transplan... Microbiota | Multiple sampli... | 18 Years - 70 Years | University Hospital, Grenoble | |
| The Swedish Study of Liver Transplantation for Non-resectable Colorectal Cancer Metastases | NCT04161092 | Colorectal Canc... Liver Metastase... Colorectal Live... | Liver transplan... Best alternativ... | 18 Years - | Vastra Gotaland Region | |
| HepatoPredict Prognostic Tool for the Decision of Liver Transplant in Hepatocellular Carcinoma | NCT04499833 | Hepatocellular ... Recurrence Tumo... | liver transplan... | 18 Years - 70 Years | Centro Hospitalar de Lisboa Central | |
| Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation | NCT06041490 | Liver Transplan... Hepatocarcinoma Recurrent Osteo... High-Risk Cance... | multi-kinase in... | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy | NCT03394365 | Epstein-Barr Vi... Solid Organ Tra... Lymphoprolifera... Allogeneic Hema... Stem Cell Trans... | tabelecleucel | - | Atara Biotherapeutics | |
| Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 ) | NCT04443322 | Liver Carcinoma Liver Transplan... | Durvalumab Inje... Lenvatinib 4 MG | 18 Years - 80 Years | RenJi Hospital | |
| De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma | NCT00328770 | Liver Carcinoma | Sirolimus | 18 Years - 70 Years | University of Alberta | |
| Heterogeneity and Evolution of hepatoceLlular Carcinoma in Post-transplant HCC Recurrence | NCT04506398 | Hepatocellular ... Liver Transplan... | liver transplan... ctDNA whole exome seq... | 18 Years - 80 Years | RenJi Hospital | |
| Liver Transplantation for Non-resectable Perihilar Cholangiocarcinoma | NCT04993131 | Perihilar Chola... Klatskin Tumor Bile Duct Cance... | Liver transplan... | 18 Years - | Oslo University Hospital | |
| HHV8 and Solid Organ Transplantation | NCT05081141 | HHV8 HHV8 Infection HHV8-Related Ma... Kaposi Sarcoma Lung Transplant... Liver Transplan... Kidney Transpla... Castleman Disea... | Diagnostic test... | 18 Years - | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | |
| Improving Outcome of Selected Patients With Non-resectable Hepatic Metastases From Colo-rectal Cancer With Liver Transplantation | NCT03803436 | Liver Metastase... Colorectal Canc... Liver Neoplasm Neoplasms | Liver transplan... Chemotherapy Chemotherapy | 18 Years - 69 Years | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| The Swedish Study of Liver Transplantation for Non-resectable Colorectal Cancer Metastases | NCT04161092 | Colorectal Canc... Liver Metastase... Colorectal Live... | Liver transplan... Best alternativ... | 18 Years - | Vastra Gotaland Region | |
| De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma | NCT00328770 | Liver Carcinoma | Sirolimus | 18 Years - 70 Years | University of Alberta | |
| Microbiota Study in Liver Transplanted Patients | NCT03507140 | Cirrhosis Hepatocellular ... Liver Transplan... Microbiota | Multiple sampli... | 18 Years - 70 Years | University Hospital, Grenoble | |
| Improving Outcome of Selected Patients With Non-resectable Hepatic Metastases From Colo-rectal Cancer With Liver Transplantation | NCT03803436 | Liver Metastase... Colorectal Canc... Liver Neoplasm Neoplasms | Liver transplan... Chemotherapy Chemotherapy | 18 Years - 69 Years | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation | NCT06409637 | Liver Cancer Liver Transplan... | FOLFOX4 regimen lenvatinib | 18 Years - 75 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy | NCT03394365 | Epstein-Barr Vi... Solid Organ Tra... Lymphoprolifera... Allogeneic Hema... Stem Cell Trans... | tabelecleucel | - | Atara Biotherapeutics | |
| Microbiota Study in Liver Transplanted Patients | NCT03507140 | Cirrhosis Hepatocellular ... Liver Transplan... Microbiota | Multiple sampli... | 18 Years - 70 Years | University Hospital, Grenoble | |
| Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant | NCT03960008 | Hepatocellular ... HCC | Stereotactic Bo... Trans-Arterial ... Doxorubin | 18 Years - | Lahey Clinic | |
| De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma | NCT00328770 | Liver Carcinoma | Sirolimus | 18 Years - 70 Years | University of Alberta | |
| PET TDM FDG-Choline as a Decision-making Tool for Routine Care on the Liver Transplant List for HCC | NCT04792801 | Hepatocellular ... Liver Transplan... | PET TDM FDG-Cho... | 18 Years - | University Hospital, Lille | |
| Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma | NCT06254248 | Liver Transplan... Hepatocellular ... Systemic Treatm... | Systemic therap... | 18 Years - 90 Years | Assistance Publique - Hôpitaux de Paris | |
| Evaluation of Combined Modality Protons and Hepatic Transplantation for Hilar Cholangiocarcinoma | NCT06434493 | Cholangiocarcin... | Proton Beam The... Concurrent oral... Cisplatin & Gem... Orthotropic Liv... | 17 Years - | The Christie NHS Foundation Trust | |
| Natural History of Liver Cirrhosis Diagnosed by Transient Elastography in HIV/HCV-coinfected Patients | NCT02693847 | Liver Cirrhosis Hepatocellular ... HIV HCV Coinfection | 18 Years - | Hospital Universitario de Valme | ||
| Colorectal Metastasis and Liver Transplantation With Organs From Deceased Donors | NCT04870879 | Colorectal Live... Colorectal Aden... Unresectable Ma... | Liver Transplan... Chemotherapy | 18 Years - 70 Years | Azienda Ospedaliera di Padova | |
| PET TDM FDG-Choline as a Decision-making Tool for Routine Care on the Liver Transplant List for HCC | NCT04792801 | Hepatocellular ... Liver Transplan... | PET TDM FDG-Cho... | 18 Years - | University Hospital, Lille | |
| Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant | NCT05027425 | Hepatocellular ... Cirrhosis Portal Hyperten... | Durvalumab Tremelimumab Liver Transplan... | 18 Years - | University of Cincinnati | |
| Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant | NCT04035876 | Hepatocellular ... Liver Transplan... | Camrelizumab pl... | 18 Years - 75 Years | Zhejiang University | |
| Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 ) | NCT04443322 | Liver Carcinoma Liver Transplan... | Durvalumab Inje... Lenvatinib 4 MG | 18 Years - 80 Years | RenJi Hospital | |
| Yttrium-90 (TARE-Y90) in Children, Adolescents, and Young Adults With Liver Tumors | NCT04315883 | Hepatoblastoma Hepatocellular ... Rhabdoid Tumor ... Undifferentiate... Pediatric Liver... Liver Tumors | Quality of Life... Transarterial R... | 0 Years - 21 Years | Nemours Children's Clinic | |
| Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant | NCT05027425 | Hepatocellular ... Cirrhosis Portal Hyperten... | Durvalumab Tremelimumab Liver Transplan... | 18 Years - | University of Cincinnati | |
| FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation | NCT06409637 | Liver Cancer Liver Transplan... | FOLFOX4 regimen lenvatinib | 18 Years - 75 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
